Table 1.
Baseline characteristics.
| Cohort 1 | Cohort 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| PSC-UC (n=17) | UC (n=17) | Healthycontrols (n=12) | p-value | PSC-UC (n=10) | UC (n=10) | Healthy controls (n=10) | p-value | |
| Male [n (%)] | 17 (100) | 17 (100) | 12 (100) | – | 10 (100) | 10 (100) | 10 (100) | – |
| Age [median (IQR)] | 41 (30-55) | 34 (31-54) | 39 (29-50) | 0.911 | 40 (35-58) | 58 (49-62) | 30 (28-53) | 0.022 |
| Age at diagnosis PSC [median (IQR)] | 33 (24-46) | – | – | – | 33 (25-37) | – | – | – |
| Duration PSC in years [median (IQR)] | 5 (2-12) | – | – | – | 7 (6-15) | – | – | – |
| Age at diagnosis UC [median (IQR)] | 27 (20-37) | 29 (19-40) | – | 0.865 | 35 (22-39) | 30 (19-46) | – | 0.796 |
| Duration UC in years [median (IQR)] | 16 (7-21) | 11 (5-15) | – | 0.218 | 9 (5-19) | 22 (14-34) | – | 0.019 |
| Medication use [n (%)] | ||||||||
| UDCA | 17 (100) | 0 (0) | – | 0.000 | 8 (80) | 0 (0) | – | 0.001 |
| Anti-TNF-α | 0 (0) | 0 (0) | – | – | 0 (0) | 0 (0) | – | – |
| Mesalazine | 17 (100) | 17 (100) | – | – | 9 (90) | 9 (90) | – | 1.000 |
| Thiopurines | 8 (47) | 9 (53) | – | 1.000 | 0 (0) | 1 (10) | – | 1.000 |
| Montreal classification [n (%)] | 0.144 | 0.164 | ||||||
| Pancolitis | 15 (88) | 10 (59) | – | 7 (70) | 6 (60) | – | ||
| Left sided | 2 (12) | 5 (29) | – | 1 (10) | 4 (40) | – | ||
| Proctitis | 0 (0) | 1 (6) | – | 2 (20) | 0 (0) | – | ||
For continuous variables the Kruskal Wallis test was used for comparing 3 groups, whereas the Mann Whitney-U test was used for comparing 2 groups. For dichotomous variables, Fisher’s Exact test was used. P-value < 0.05 was considered statistically significant. PSC, primary sclerosing cholangitis; UC, ulcerative colitis; IQR, interquartile range; UDCA, Ursodeoxycholic acid.